Tokyo, Japan, November 13, 2025 – RealizeEdge Partners Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Yoshitsugu Shitaka, Ph.D.; “RealizeEdge Partners”) today announced that it has entered into a collaborative alliance with Alchemedicine Co., Ltd. (Location: Tsukuba, Ibaraki; CEO & Founder: Keigo Tanaka, Ph.D.; hereinafter "Alchemedicine") to support the establishment of a new company that will develop ALM0106, a novel therapeutic agent for inflammatory bowel disease (IBD).

ALM0106 is a new drug candidate compound discovered using Alchemedicine's unique, proprietary drug design technology, HiSAP®, and is expected to be first-in-class for this indication.

With the combined strength of Alchemedicine’s drug discovery capabilities and RealizeEdge Partners' business development expertise, we will deliver greater value to the new company to be established, realizing the goal of bringing this groundbreaking new therapeutic agent to patients.

About Alchemedicine

Alchemedicine is a biotech company focusing on the discovery of small molecule drugs using HiSAP®, a novel medchem platform, under a vision of “We successively discover life-changing treatments for various diseases that make a lasting positive contribution to society”.
Website: https://alchemedicine.com/en/company

About RealizeEdge Partners

RealizeEdge Partners is a Tokyo-based startup studio established in April 2025. We support innovators with breakthrough ideas to accelerate the creation of drug discovery startups transforming health and brightening lives by integrating scientific excellence with strategic and operational support.
Website: https://realizeedge.com/en/